ASXL1 and leukemia: Given the promising results in murine leukemia models with co-occurring mutations, we then evaluated the ex vivo activity of TP-0903 and TKIs in human primary samples with coexisting recurrent mutations (e.g., FLT3-ITD, IDH1/2, ASXL1, DNMT3A, NPM1, and SRSF2).